- Home
- LGCB vs GTBP Comparison
LGCB vs GTBP Comparison
Compare LGCB & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCB
- GTBP
- Stock Information
- Founded
- LGCB 2011
- GTBP 1965
- Country
- LGCB Japan
- GTBP United States
- Employees
- LGCB N/A
- GTBP N/A
- Industry
- LGCB
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- LGCB
- GTBP Health Care
- Exchange
- LGCB Nasdaq
- GTBP Nasdaq
- Market Cap
- LGCB 5.9M
- GTBP 6.6M
- IPO Year
- LGCB 2023
- GTBP N/A
- Fundamental
- Price
- LGCB $0.23
- GTBP $3.06
- Analyst Decision
- LGCB
- GTBP
- Analyst Count
- LGCB 0
- GTBP 0
- Target Price
- LGCB N/A
- GTBP N/A
- AVG Volume (30 Days)
- LGCB 1.2M
- GTBP 21.7K
- Earning Date
- LGCB 11-29-2024
- GTBP 11-14-2024
- Dividend Yield
- LGCB N/A
- GTBP N/A
- EPS Growth
- LGCB N/A
- GTBP N/A
- EPS
- LGCB N/A
- GTBP N/A
- Revenue
- LGCB $8,500,375.00
- GTBP N/A
- Revenue This Year
- LGCB N/A
- GTBP N/A
- Revenue Next Year
- LGCB N/A
- GTBP N/A
- P/E Ratio
- LGCB N/A
- GTBP N/A
- Revenue Growth
- LGCB N/A
- GTBP N/A
- 52 Week Low
- LGCB $0.20
- GTBP $1.92
- 52 Week High
- LGCB $5.71
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- LGCB 34.41
- GTBP 55.00
- Support Level
- LGCB $0.21
- GTBP $2.73
- Resistance Level
- LGCB $0.24
- GTBP $3.20
- Average True Range (ATR)
- LGCB 0.04
- GTBP 0.35
- MACD
- LGCB 0.02
- GTBP -0.04
- Stochastic Oscillator
- LGCB 21.45
- GTBP 42.65
About LGCB Linkage Global Inc
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides global e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, global store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.